Prospective non-interventional study (NIS) to examine patient-reported outcomes and real-world clinical data in patients with HER2-positive or HER2-low unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan
18 Years - 130 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Sept 2023 by AstraZeneca
No locations available
Cohort 1 containing patients with documented HER2-positive unresectable or metastatic BC receiving T-DXd for 2L treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.
Cohort 2 containing patients with documented HER2-low unresectable or metastatic BC receiving T DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice.